OncoMatch/Clinical Trials/NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Is NCT07441694 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including INCA036978 and Standard disease-directed therapy for myeloproliferative neoplasms.
Treatment: INCA036978 · Standard disease-directed therapy — This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Prior therapy
Cannot have received: MPN-directed therapy
Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
Cannot have received: radiation therapy
Prior radiation therapy within 28 days before the first dose of study treatment.
Cannot have received: allogeneic stem-cell transplantation
Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham · Birmingham, Alabama
- City of Hope-Lennar Foundation Cancer Center · Irvine, California
- Usc Norris Comprehensive Cancer Center · Los Angeles, California
- UCLA Medical Hematology & Oncology · Los Angeles, California
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify